Alnylam May Not Reach Partnership Goal for ‘09, Partner Cubist to Focus on Follow-On RSV Rx | GenomeWeb

This story has been updated to include comments from Alnylam officials and details about the company’s respiratory syncytial virus program.

By Doug Macron

Alnylam Pharmaceuticals said last week that it may not reach its previously stated goal of forging two or more new “major” industry partnerships before the end of the year despite continued interest from potential biotech and pharmaceutical allies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.